KemPharm has received the Orphan Drug Designation from the US Food and Drug Administration (FDA) for serdexmethylphenidate (SDX) to treat rare neurological sleep disorder, idiopathic hypersomnia (IH).
21 Nov 2022
18 Nov 2022
Marinus Pharmaceuticals has signed a collaboration and supply agreement with Tenacia Biotechnology (Shanghai), a China-based biotechnology company focused on the development of innovative treatments for central nervous system (CNS) disorders.
22 Aug 2022
The US Food and Drug Administration (FDA) has approved Axsome Therapeutics’ Auvelity (dextromethorphan HBr -bupropion HCl) to treat adult patients with major depressive disorder (MDD).
05 Aug 2022
Acadia Pharmaceuticals has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) on its supplemental New Drug Application (sNDA) for NUPLAZID (pimavanserin).
15 Jul 2022
SK Biopharmaceuticals has signed a licensing agreement with Eurofarma, a Brazilian pharmaceutical company, to develop and commercialise cenobamate in Latin America for epilepsy treatment.
19 May 2022
SwanBio Therapeutics, a gene therapy company, has raised $56m through Series B financing round to advance gene therapies for neurological conditions.
05 May 2022
Apnimed has raised $62.5m funding in a Series C round led by new investor Sectoral Asset Management to advance new pharmaceutical treatments development for obstructive sleep apnea (OSA) and related sleep disorders.
02 May 2022
The US Food and Drug Administration (FDA) has approved an expanded indication for Supernus Pharmaceuticals’ Qelbree (viloxazine extended-release capsules) to treat attention deficit hyperactivity disorder (ADHD) in adult patients of the age 18 and above.
28 Apr 2022
Pfizer and Biohaven Pharmaceutical have announced receipt of marketing authorisation from the European Commission (EC) for Vydura (rimegepant).
23 Feb 2022
AbbVie has submitted a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for its therapy cariprazine (VRAYLAR) to treat major depressive disorder (MDD).